Tags

Type your tag names separated by a space and hit enter

Oral contraceptives and breast disease.
Fertil Steril. 1991 Nov; 56(5):799-819.FS

Abstract

Epidemiologic data support the hypothesis that the types of OCs used before the mid-1970s protected against most forms of benign breast disease. It is unclear whether current low-dose progestogen OCs will confer the same protection. Further studies are necessary to clarify this. For breast cancer, the relationship is more complex. It is possible that prolonged use of high-dose OCs exert a small increased risk for breast cancer development in women before age 45. Furthermore, prolonged use before a first term pregnancy may result in a small increase in risk for breast cancer before age 45. Studies evaluating the effect of current low-dose OCs are necessary to elucidate what, if any, effect they may have on breast cancer development. Furthermore, as our population ages, studies will be able to determine what effect, if any, may be present in women over age 60, those women with the highest underlying risk of breast cancer. And finally, more research of basic breast tissue physiology and the effect of endogenous and exogenous hormones on this complex organ is needed.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Francis Scott Key Medical Center, Baltimore, Maryland.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1936311

Citation

McGonigle, K F., and G R. Huggins. "Oral Contraceptives and Breast Disease." Fertility and Sterility, vol. 56, no. 5, 1991, pp. 799-819.
McGonigle KF, Huggins GR. Oral contraceptives and breast disease. Fertil Steril. 1991;56(5):799-819.
McGonigle, K. F., & Huggins, G. R. (1991). Oral contraceptives and breast disease. Fertility and Sterility, 56(5), 799-819.
McGonigle KF, Huggins GR. Oral Contraceptives and Breast Disease. Fertil Steril. 1991;56(5):799-819. PubMed PMID: 1936311.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral contraceptives and breast disease. AU - McGonigle,K F, AU - Huggins,G R, PY - 1991/11/1/pubmed PY - 1991/11/1/medline PY - 1991/11/1/entrez KW - Biology KW - Body Weight KW - Breast Cancer KW - Cancer KW - Case Control Studies KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive History KW - Contraceptive Usage KW - Delayed Childbearing KW - Demographic Factors KW - Diseases KW - Endocrine System KW - Estradiol KW - Estrogens KW - Family Planning KW - Fertility KW - Fertility Measurements KW - Fibroadenosis KW - First Birth KW - Hormone Receptors KW - Hormones KW - Literature Review KW - Mammary Gland Effects KW - Membrane Proteins KW - Neoplasms KW - Neoplasms, Benign KW - Nulliparity KW - Obesity KW - Parity KW - Physiology KW - Population KW - Population Dynamics KW - Pregnancy History KW - Previous Practice KW - Progestational Hormones KW - Progesterone KW - Reproductive Behavior KW - Research Methodology KW - Risk Factors KW - Studies SP - 799 EP - 819 JF - Fertility and sterility JO - Fertil. Steril. VL - 56 IS - 5 N2 - Epidemiologic data support the hypothesis that the types of OCs used before the mid-1970s protected against most forms of benign breast disease. It is unclear whether current low-dose progestogen OCs will confer the same protection. Further studies are necessary to clarify this. For breast cancer, the relationship is more complex. It is possible that prolonged use of high-dose OCs exert a small increased risk for breast cancer development in women before age 45. Furthermore, prolonged use before a first term pregnancy may result in a small increase in risk for breast cancer before age 45. Studies evaluating the effect of current low-dose OCs are necessary to elucidate what, if any, effect they may have on breast cancer development. Furthermore, as our population ages, studies will be able to determine what effect, if any, may be present in women over age 60, those women with the highest underlying risk of breast cancer. And finally, more research of basic breast tissue physiology and the effect of endogenous and exogenous hormones on this complex organ is needed. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/1936311/Oral_contraceptives_and_breast_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)54647-0 DB - PRIME DP - Unbound Medicine ER -